viewBausch Health Cos Inc

Bausch Health’s 2Q loss widens, but revenue beats Street estimates

Investors sent shares of the drugmaker up after it said it still expects full-year revenue of US$8.15bn to US$8.35bn

Bausch & Lomb product
A trio of drugs are hitting the market this year to replace sales of drugs facing stiffer competition from generics

Bausch Health Cos Inc (NYSE: BHC), formerly known as Valeant Pharmaceuticals, reported a wider-than-expected loss in the second quarter Tuesday despite beating Wall Street revenue estimates.

For the quarter ended June 2018, the well-diversified pharma company swung to a loss of US$873 mln, or US$2.49 a share, wider than the loss of US$38mln, or US$0.11 a share, posted in the year-earlier period. Revenue was approximately US$2.128bn. The consensus earnings estimate called for EPS of US$0.80 on revenue of US$2.063bn.

Investors gave the drug maker a pass after it explained that the loss was mostly due to an asset impairment linked to the loss of exclusivity on a product it didn’t name. A trio of drugs are hitting the market this year with the goal of replacing sales that are reliant on keystone drugs poised to face greater competition from generics.

As a result, shares of Bausch Health were buoyant, up over 6% to US$23.92.

All eyes were aptly focused on sales in the company’s biggest business, Bausch + Lomb which logged revenues of US$1.209bn for the second quarter, a decrease of US$14mln, or 1% compared to the same period last year. 

"The company delivered overall organic growth, driven by solid results in our Salix and Bausch + Lomb/International segments, which together represented 78% of our business in the quarter," Bausch Health CEO Joseph C Papa said in a statement.

The Canada-based company said it realigned into four reporting segments in the quarter, namely Bausch and Lomb/International, its eye treatments; Salix, its gastroenterology business; Ortho Dermatologics; and diversified products.

Bausch Health said sales of its potential blockbuster gastrointestinal drug Xifaxan grew 26% and contributed the most to the Salix segment’s US$441mln kitty.

The company said it still expects full-year revenue of US$8.15bn to US$8.35bn.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter@UttaraProactive 

Quick facts: Bausch Health Cos Inc

Price: 31.42 USD

Market: NYSE
Market Cap: $11.17 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 17 hours ago

2 min read